Trial Profile
An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2014
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 24 Aug 2012 New trial record